Encapsulate (Biotech Startup)
City/Town where Organization Located
Company/organization description (<500 characters)
At Encapsulate LLC, we have developed an automated tumor-on-a-chip system that can grow patient-derived cancer cells ex vivo, and screen them against chemotherapeutic drugs. With this technology the oncologist can choose the most effective chemotherapy drug prior to treatment on an individualized basis. This will I) reduce the number of unnecessary chemotherapy cycles a patient undergoes, II) lower the costs and duration of treatment, III) increase the success rates of treatment, and IV) improve the patient’s overall quality of life. Our mission is to offer personalized cancer therapy screening in the most accurate, expedited, and cost-effective manner.
Tell us about the milestones your venture accomplished in 2019, eg., key team members added, revenue level achieved, major sales made or endorsements received, successful exit, etc... (<500 characters)
2019 was an amazing year for Encapsulate. We won the most prestigues award of NASA for research startups, "research in space". With this award, for $700,000, awarded by NASA and International Space Station, our technology will be implemented in the space station for cancer research. We started our first clinical trial with UConn Health and have expanded it to Hartford Healthcare in December. Moreover, we have been awarded multiple grants, such as CTNext Thirdbridge, CT Biopipeline, and UConn START Grant. Encapsulate also filed its first patent in 2019.
Stage: Does your venture generate revenue? YES or NO
What CT entrepreneur ecosystem resources (spaces, programs, events, schools, etc.) have helped you succeed? (<500 characters)
Encapsulate is based in UConn Technology Incubation Program (UCONN TIP). We have also participated in two accelerator programs in New England: MassChallenge Boston and Digital Health Connecticut (DHCT). We also have been mentored by a private accelerator program in Tolland, CT, led by Nerac Inc., XCellR8.
What people are saying about Encapsulate...
Encapsulate is developing an automated tumor-on-a-chip system that can grow patients cancer cells outside the body, and test the efficacy of chemotherapeutic drugs against them to advocate for the best course of treatment. This can help the oncologists in deciding the first-line of treatment for patients prior to starting treatment. Using this platform and choosing the most efficient cancer drug from the beginning will I) reduce the number of chemotherapy cycles a patient undergoes, II) lower the costs and duration of treatment, III) increase the success rates of treatment, and IV) improve the patient’s overall quality of life. Their mission is to offer personalized cancer therapy screening in the most accurate, expedited, and cost-effective manner.In 2019, Encapsulate was selected as one of the 10 teams participating in the inaugural Digital Health CT accelerator program in Hartford run by Startupbootcamp and sponsored by Hartford HealthCare. In addition, Encapsulate was selected to participate in MassChallenge and was awarded the Boeing and ISS National Lab Technology in Space Prize. Jennifer Murphy
Encapsulate is a pre-revenue startup which has developed an automated system that can grow patient-derived cancer cells ex vivo, and screen them against cancer drugs. With this technology, the oncologist can choose the most effective chemotherapy drug prior to treatment on an individualized basis. Encapsulate was one of the most successful biotech startups in New England in 2019. They have been granted by multiple state and national funding sources, such as Third Bridge Grant, CT Biopipeline, and START Grant. Moreover, they were one of the only three companies from CT that have been admitted for one of the most prestigious accelerator programs all over the world, MassChallenge. Most importantly, in Fall 2019, they have been awarded one of the most prestigious research awards worldwide, NASA/International Space Station “Technology in Space Prize” for $700K. Currently, they are collaborating with NASA/ISS national lab to implement their technology in the space station for cancer research purposes. They have also started their partnership with Hartford Healthcare and UConn Health for the clinical studies of their technology. Leila Daneshmandi